The domestic HMO（human milk oligosaccharide）clinical study project for Chinese infants has officially started, sponsored by Nestlé Research & Development China and Wyeth Nutrition. Shanghai Jiao Tong University School of Medicine's Xinhua Hospital is in charge of the project.

Collaborating with clinical centers in elite hospitals around the country, the project aims to verify the clinical effectiveness of the two HMOs that have been approved for Chinese infants.

Wyeth Nutrition, the nutrition product maker, launched the first infant formula with two essential HMOs, offering more nutrition options to newborns in the country.

This clinically proven product offers substantial advantages for the general well-being of newborns between the ages of 0 and 12 months, according to Wyeth Nutrition. The company said it diminishes lower respiratory tract infections by 55 percent, bronchitis by 70 percent, and the likelihood of using antibiotics by 53 percent.

Shiela Qiu, regional business head of Wyeth Nutrition Greater China Region, said: "Wyeth Nutrition is dedicated to fostering the further growth of the Chinese infant nutrition market, bringing together worldwide research resources and quickening local innovation, and offering Chinese newborns more complete early-life nutrition options."